Bonnie Ramsey, MD, Program Director and Director,
Dr. Ramsey has been a clinical investigator in the field of cystic fibrosis (CF) for over 25 years. She is the co-PI of the Clinical Translational Science Award at the University of Washington, Vice Chair for Research of the Department of Pediatrics, and Director of the Coordinating Center of the Cystic Fibrosis Therapeutics Development Network, a clinical trials network composed of 77 research sites throughout the US. She is a Professor of Pediatrics holding an Endowed Chair in Cystic Fibrosis Research. She is an elected Fellow of the American Pediatric Society and the American Association of Physicians. Dr. Ramsey along with Dr. E. Peter Greenberg will oversee all administrative and scientific aspects of the center. In addition, Dr. Ramsey is the Director for the Clinical Core of the Seattle CFRTC. She is an internationally recognized leader in clinical research in cystic fibrosis. Her early research was instrumental in moving inhaled tobramycin solution from early translational studies to eventual FDA approval in the United States. She also launched the CFF TDN in conjunction with the CF Foundation in 1998 and has successfully overseen the network's rapid growth and development.
E. Peter Greenberg, PhD, Co-Program Director and Director, Microbiology Core
Dr. Greenberg is a Professor
of Microbiology and is a Multi-PI with Dr. Ramsey. In addition, Dr.
Greenberg is also the Director for the Microbiology Core of the Seattle
CFRTC. Dr. Greenberg is currently Director of the UW CF Foundation
supported Research Development Program (RDP). He has served
continuously as a member of the CFF Research and Training Committee for
the past 12 years. He is an elected member of the National Academy of
Sciences and the American Academy of Arts and Sciences. He has made
major contributions to our understanding of the fundamental biology
underlying the chronicity of CF lung infections and the regulation of
virulence gene expression in P.
aeruginosa and other CF pathogens. Dr. Greenberg is an authority
on microbemicrobe interactions. This is an area of increasing relevance
as we come to understand that the CF lung represents a polymicrobial
community. Furthermore, as research efforts on the intestinal
microbiota of CF patients begins to move ahead this expertise will be
invaluable. Dr. Greenberg's lab is currently located on
the third floor of the K-wing of UW Medicine in laboratories adjacent
to the CF Foundation supported RDP Biofilm Core.
Samuel Miller, MD, Director, Genomics Core
Dr. Miller is a Professor of Medicine, Microbiology, and Genome Sciences. He is a physician, infectious diseases specialist, and experienced researcher in bacterial pathogenesis and host-pathogen interaction. He has over 15 years experience as a PI in the research area of Genomic Sciences. He is also experienced in the area of cystic fibrosis (CF), and is the former Director of the Cystic Fibrosis Research and Development Program at the University of Washington, now directed by E. Pete Greenberg, and on which he retains direction of the Genomics Core. Dr. Miller also functions as the Director of a Research Center of Excellence in Biodefense and Emerging Infectious Diseases for the region.
Charles W. Frevert, DVM, ScD.
Dr. Frevert is an Associate Professor of Comparative
Medicine and Pulmonary and Critical Care Medicine. His research focuses
on the role of proteoglycans in controlling the innate immune response
to infection with an emphasis on understanding the mechanisms whereby
glycosaminoglycans control chemokine function and neutrophil migration
in the lungs. Dr. Frevert has considerable experience with all the
histology and imaging technologies that the Immunology Core provides
and with the development of animal models of inflammation and
infection. He was the Director of the Molecular Imaging Core at the VA
Puget Sound Medical Center for 8 years, and he is currently the
Director of the Histology and Imaging Core and Co-Director of the
Comparative Pathology Program.